Skip to main content

Adamas Pharmaceuticals, Inc. (ADMS)

NASDAQ: ADMS · Delayed Price · USD
4.86 0.08 (1.67%)
Sep 23, 2021 4:00 PM EDT - Market closed
Market Cap219.09M
Revenue (ttm)82.47M
Net Income (ttm)-55.11M
Shares Out45.46M
EPS (ttm)-1.60
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume70,668
Open4.83
Previous Close4.78
Day's Range4.74 - 4.89
52-Week Range2.96 - 9.15
Beta2.68
AnalystsBuy
Price Target8.79 (+80.9%)
Est. Earnings DateNov 4, 2021

About ADMS

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet ...

IndustryBiotechnology
IPO DateApr 10, 2014
CEONeil McFarlane
Employees138
Stock ExchangeNASDAQ
Ticker SymbolADMS
Full Company Profile

Financial Performance

In 2020, ADMS's revenue was $74.46 million, an increase of 36.28% compared to the previous year's $54.64 million. Losses were -$57.40 million, -45.43% less than in 2019.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for ADMS stock is "Buy." The 12-month stock price forecast is 8.79, which is an increase of 80.86% from the latest price.

Price Target
$8.79
(80.86% upside)
Analyst Consensus: Buy

News

Adamas Announces GOCOVRI Presentations at the Upcoming International Parkinson and Movement Disorder Society's (MDS) ...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

1 week ago - Business Wire

Adamas Announces New Employment Inducement Grants

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted seven new employees restricte...

1 week ago - Business Wire

Adamas to Present at Upcoming September Investor Conferences

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

3 weeks ago - Business Wire

Adamas Announces New Employment Inducement Grant

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted three new employees restricte...

1 month ago - Business Wire

Adamas Pharmaceuticals (ADMS) Reports Q2 Loss, Lags Revenue Estimates

Adamas (ADMS) delivered earnings and revenue surprises of 0.00% and -1.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Adamas Reports Second Quarter 2021 Financial Results

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

1 month ago - Business Wire

Adamas to Announce Second Quarter Financial Results and Host Conference Call on August 9, 2021

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report second quarter 2021 financial results on Monday, August 9, after market clos...

1 month ago - Business Wire

Adamas Pharmaceuticals (ADMS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Adamas Announces Issuance of New Patents for GOCOVRI and ADS-4101

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

2 months ago - Business Wire

Adamas Announces New Employment Inducement Grant

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted four new employees restricted...

2 months ago - Business Wire

Adamas to Present at Upcoming William Blair Biotech Focus Conference

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

2 months ago - Business Wire

Implied Volatility Surging for Adamas Pharmaceuticals (ADMS) Stock Options

Investors need to pay close attention to Adamas Pharmaceuticals (ADMS) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

Adamas to Present at Upcoming SVB Leerink CNS Forum

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

3 months ago - Business Wire

Adamas Announces New Employment Inducement Grant

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted three new employees restricte...

3 months ago - Business Wire

New Data Analysis Supports GOCOVRI as an Important Treatment for Motor Complications for People With Parkinson's Disease

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

3 months ago - Business Wire

Adamas to Present at Upcoming June Conferences

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

3 months ago - Business Wire

Adamas Pharmaceuticals (ADMS) Reports Q1 Loss, Misses Revenue Estimates

Adamas (ADMS) delivered earnings and revenue surprises of 25.00% and -1.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Adamas Reports First Quarter 2021 Financial Results

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

4 months ago - Business Wire

Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: Should You Buy?

Adamas (ADMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Adamas to Present at Upcoming BofA Conference

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

4 months ago - Business Wire

Adamas Launches “Picture More Time” Campaign to Raise Awareness and Understanding of the Impact of OFF Time and Dyski...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

4 months ago - Business Wire

Adamas to Announce First Quarter Financial Results and Host Conference Call on May 10, 2021

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report first quarter 2021 financial results on Monday, May 10, after market close. ...

4 months ago - Business Wire

Survey data detailing impact of OFF time and dyskinesia in people affected by Parkinson's disease presented at Americ...

TUCSON, Ariz. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Parkinson & Movement Disorder Alliance (PMD Alliance, www.pmdalliance.org) and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to de...

5 months ago - Business Wire

Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

5 months ago - Business Wire

Adamas to Present at Upcoming Needham Conference

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neuro...

5 months ago - Business Wire